These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29249470)

  • 21. Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial.
    Kitai T; Grodin JL; Mentz RJ; Hernandez AF; Butler J; Metra M; McMurray JJ; Armstrong PW; Starling RC; O'Connor CM; Swedberg K; Tang WH
    Eur J Heart Fail; 2017 Feb; 19(2):241-249. PubMed ID: 27634557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure.
    Kotecha D; Flather MD; Altman DG; Holmes J; Rosano G; Wikstrand J; Packer M; Coats AJS; Manzano L; Böhm M; van Veldhuisen DJ; Andersson B; Wedel H; von Lueder TG; Rigby AS; Hjalmarson Å; Kjekshus J; Cleland JGF;
    J Am Coll Cardiol; 2017 Jun; 69(24):2885-2896. PubMed ID: 28467883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is heart rate important for patients with heart failure in atrial fibrillation?
    Cullington D; Goode KM; Zhang J; Cleland JG; Clark AL
    JACC Heart Fail; 2014 Jun; 2(3):213-20. PubMed ID: 24952686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction.
    Foster JL; Bobadilla RV
    J Am Assoc Nurse Pract; 2016 Nov; 28(11):576-582. PubMed ID: 27215699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
    Böhm M; Komajda M; Borer JS; Ford I; Maack C; Tavazzi L; Moyne A; Swedberg K;
    Eur J Heart Fail; 2018 Feb; 20(2):373-381. PubMed ID: 29027329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
    Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
    Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left ventricular ejection fraction as therapeutic target: is it the ideal marker?
    Katsi V; Georgiopoulos G; Laina A; Koutli E; Parissis J; Tsioufis C; Nihoyannopoulos P; Tousoulis D
    Heart Fail Rev; 2017 Nov; 22(6):641-655. PubMed ID: 28601914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Catheter ablation of atrial fibrillation in patients with heart failure: impact of maintaining sinus rhythm on heart failure status and long-term rates of stroke and death.
    Ullah W; Ling LH; Prabhu S; Lee G; Kistler P; Finlay MC; Earley MJ; Sporton S; Bashir Y; Betts TR; Rajappan K; Thomas G; Duncan E; Staniforth A; Mann I; Chow A; Lambiase P; Schilling RJ; Hunter RJ
    Europace; 2016 May; 18(5):679-86. PubMed ID: 26843584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. β-Blockade in Heart Failure With Reduced Ejection Fraction: Does Heart Rate Control Influence Readmissions?
    Owens RE; Twilla JD; Self TH; Alshaya AI; Metra CJ; Cummings C; Oliphant CS
    J Pharm Pract; 2018 Feb; 31(1):40-45. PubMed ID: 28737066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New onset heart failure--Clinical characteristics and short-term mortality. A RICA (Spanish registry of acute heart failure) study.
    Franco J; Formiga F; Chivite D; Manzano L; Carrera M; Arévalo-Lorido JC; Epelde F; Cerqueiro JM; Serrado A; Pérez-Barquero MM;
    Eur J Intern Med; 2015 Jun; 26(5):357-62. PubMed ID: 25936936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel drugs for heart rate control in heart failure.
    Bielecka-Dabrowa A; von Haehling S; Rysz J; Banach M
    Heart Fail Rev; 2018 Jul; 23(4):517-525. PubMed ID: 29594814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure.
    Rosa GM; Ferrero S; Ghione P; Valbusa A; Brunelli C
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):279-91. PubMed ID: 24377458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Experience with Ivabradine in Acute Heart Failure.
    Pascual Izco M; Alonso Salinas GL; Sanmartín Fernández M; Del Castillo Carnevalli H; Jiménez Mena M; Camino López A; Zamorano Gómez JL
    Cardiology; 2016; 134(3):372-4. PubMed ID: 27100325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
    Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Robertson M; Ford I;
    Int J Cardiol; 2013 Dec; 170(2):182-8. PubMed ID: 24225201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value.
    Pellicori P; Zhang J; Lukaschuk E; Joseph AC; Bourantas CV; Loh H; Bragadeesh T; Clark AL; Cleland JG
    Eur Heart J; 2015 Mar; 36(12):733-42. PubMed ID: 25336215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heart rate and its reduction in chronic heart failure and beyond.
    Nikolovska Vukadinović A; Vukadinović D; Borer J; Cowie M; Komajda M; Lainscak M; Swedberg K; Böhm M
    Eur J Heart Fail; 2017 Oct; 19(10):1230-1241. PubMed ID: 28627045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.
    Machino-Ohtsuka T; Seo Y; Ishizu T; Sugano A; Atsumi A; Yamamoto M; Kawamura R; Machino T; Kuroki K; Yamasaki H; Igarashi M; Sekiguchi Y; Aonuma K
    J Am Coll Cardiol; 2013 Nov; 62(20):1857-65. PubMed ID: 23916940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis of heart failure treated with digoxin or with ivabradine: A cohort study in the community.
    Guzman M; Gomez R; Romero SP; Aranda R; Andrey JL; Pedrosa MJ; Egido J; Gomez F
    Int J Clin Pract; 2018 Nov; 72(11):e13217. PubMed ID: 30248211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
    Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
    Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial.
    Edelmann F; Musial-Bright L; Gelbrich G; Trippel T; Radenovic S; Wachter R; Inkrot S; Loncar G; Tahirovic E; Celic V; Veskovic J; Zdravkovic M; Lainscak M; Apostolović S; Neskovic AN; Pieske B; Düngen HD;
    JACC Heart Fail; 2016 Feb; 4(2):140-149. PubMed ID: 26682793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.